Academic or other sponsor

Yale University

49 registered trials on this registry, 13 recruiting now. An academic sponsor is usually answering a scientific question rather than seeking approval, which changes what its trials are designed to show.

Registered trials

Recruiting

In Phase 3

With results posted

Working on

Substances

Trials

All 49 trials

Trial	Status	Phase	Substance	Sites
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence StudyNCT06713616 · Yale University	Recruiting	Phase 3	ketamine	8
The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseNCT07610369 · Yale University	Recruiting	Phase 2	psilocybin	1
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsNCT05786066 · Yale University	Recruiting	Phase 2	ketamine	1
Imaging Depression in Parkinson's DiseaseNCT06402955 · Yale University	Recruiting	Phase 2	ketamine	1
MDMA in Borderline Personality DisorderNCT06683014 · Yale University	Recruiting	Phase 2	mdma	1
Enhancing Week-long Psychological Treatment for PTSD With KetamineNCT05737693 · Yale University	Recruiting	Phase 2	ketamine	2
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)NCT06070649 · Yale University	Recruiting	Phase 1	dmt	1
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)NCT06160284 · Yale University	Recruiting	Phase 1	psilocybin	1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponseNCT05915013 · Yale University	Recruiting	Phase 1	ketamine	1
Open-Label Psilocybin Study in Transdiagnostic PopulationNCT06442423 · Yale University	Recruiting	Phase 1	psilocybin	1
Psilocybin as a Treatment for Chronic Pain in SmokersNCT07118332 · Yale University	Recruiting	Early Phase 1	psilocybin	2
Mechanistic Studies of Psilocybin in Headache DisordersNCT06464367 · Yale University	Recruiting	Early Phase 1	psilocybin	1
The OBSERVE ProtocolNCT06725277 · Yale University	Recruiting	N/A	ketamine	8
Ketamine Infusion for Adolescent Depression and AnxietyNCT02579928 · Yale University	Completed	Phase 4	ketamine	2
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and EfficacyNCT03889756 · Yale University	Terminated	Phase 2 / Phase 3	ketamine	1
Psilocybin-Assisted Physical Therapy in Chronic Low Back PainNCT07306364 · Yale University	Not yet recruiting	Phase 2	psilocybin	1
Ketamine for the Treatment of Depression in Parkinson's DiseaseNCT04944017 · Yale University	Completed	Phase 2	ketamine	1
Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous KetamineNCT04613453 · Yale University	Terminated	Phase 2	ketamine	1
Trial of Ketamine and Lithium Therapy in Bipolar DepressionNCT01768767 · Yale University	Withdrawn	Phase 2	ketamine	—
Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure TherapyNCT02727998 · Yale University	Terminated	Phase 2	ketamine	1
Examining the Impact of Sirolimus on Ketamine's Antidepressant EffectsNCT02487485 · Yale University	Completed	Phase 2	ketamine	2
Ketamine Infusion for Obsessive-Compulsive DisorderNCT01349231 · Yale University	Completed	Phase 2	ketamine	1
The Effects of Psilocybin on Social ConnectednessNCT07693153 · Yale University	Not yet recruiting	Phase 1	psilocybin	1
Effects of Repeated Psilocybin Dosing in OCDNCT05370911 · Yale University	Active, not recruiting	Phase 1	psilocybin	2
The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.NCT03752918 · Yale University	Withdrawn	Phase 1	mdma	1
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderNCT03554174 · Yale University	Active, not recruiting	Phase 1	psilocybin	1
Fixed Order, Open-Label, Dose-Escalation Study of DMT in HumansNCT04711915 · Yale University	Active, not recruiting	Phase 1	dmt	1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot TrialNCT03367533 · Yale University	Completed	Phase 1	ketamine	1
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.NCT03356483 · Yale University	Completed	Phase 1	psilocybin	1
Repeat Dosing of Psilocybin in Migraine HeadacheNCT04218539 · Yale University	Completed	Phase 1	psilocybin	1
Psilocybin for the Treatment of Cluster HeadacheNCT02981173 · Yale University	Completed	Phase 1	psilocybin	1
Psilocybin for the Treatment of Migraine HeadacheNCT03341689 · Yale University	Completed	Phase 1	psilocybin	1
Effects of Psilocybin in Concussion HeadacheNCT03806985 · Yale University	Terminated	Phase 1	psilocybin	1
Ketamine for Low Mood States in the ERNCT01209845 · Yale University	Completed	Phase 1	ketamine	1
Ketamine for Depression and Alcohol DependenceNCT01551329 · Yale University	Completed	Phase 1	ketamine	1
Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous KetamineNCT02289248 · Yale University	Completed	Phase 1	ketamine	2
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) AntagonismNCT02675530 · Yale University	Completed	Phase 1	ketamine	1
Psilocybin Microdosing on Cognition, Mood and Quality of LifeNCT07449351 · Yale University	Not yet recruiting	Early Phase 1	psilocybin	1
Examining The Effect Of Ketamine On Glutamate/Glutamine CyclingNCT02037035 · Yale University	Completed	Early Phase 1	ketamine	1
Ketamine Infusion for Social Anxiety DisorderNCT02083926 · Yale University	Completed	Early Phase 1	ketamine	1
Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine TreatmentNCT06139016 · Yale University	Completed	Not applicable	ketamine	1
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · Yale University	Terminated	N/A	lsd, psilocybin, dmt	2
Imaging SV2A in Mood DisordersNCT02734602 · Yale University	Active, not recruiting	Not applicable	ketamine	1
Role Of Non-Specific Effects in The Treatment of Depression With EsketamineNCT05910775 · Yale University	Terminated	Not applicable	ketamine	1
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse PreventionNCT04760652 · Yale University	Completed	Not applicable	ketamine	3
Long Term Follow Up KET-PDNCT06164756 · Yale University	Enrolling by invitation	N/A	ketamine	1
Ketamine/Placebo Family History Positive StudyNCT00588952 · Yale University	Completed	Not applicable	ketamine	1
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant DepressionNCT03027362 · Yale University	Completed	Not applicable	ketamine	1
PET Imaging of mGLuR5 With Drug ChallengeNCT01691092 · Yale University	Completed	Not applicable	ketamine	3

Sponsor attribution is the lead sponsor recorded on ClinicalTrials.gov API v2. Collaborators are not counted here. Data build 2026-08-25.